Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes
Launched by NOVO NORDISK A/S · Dec 10, 2008
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 2 diabetes diagnosed for at least 6 months
- • Insulin-naive (less than or equal to 1 week of daily use of insulin therapy)
- • Treatment with metformin as monotherapy or in combination therapy with other OAD(s) for at least 3 months prior to this trial
- • Currently on metformin greater than or equal to 1000 mg/day for at least 2 weeks
- • Currently at least one of other OAD(s) reaching at least one-half of the recommended maximum dose for at least 2 weeks
- • Glycosylated haemoglobin (HbA1c) between 7.5-11.0%
- • Body Mass Index (BMI) between 18.5 - 35.0 kg/m\^2
- • Be able and willing to perform continuous glucose monitoring system (CGMS ) and self-monitored blood glucose (SMBG)
- Exclusion Criteria:
- • Known or suspected allergy to trial product(s) or related products
- • Any contraindication of metformin
- • Receipt of investigational drug within the last 3 months prior to this trial
- • Any history of chronic insulin therapy (more than 1 week of daily use)
- • Systemically treated with thiazolidinediones (TZDs) for more than one month within 6 months prior to this trial
- • Pregnancy, nursing mother, or unwillingness to use adequate contraception
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Global Clinical Registry (GCR, 1452)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials